ERC Starting Grant · 2024
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes mellitus (T2DM). However, a subset of patients does not respond to these agents or develop treatment resistance, which poses a significant clinical challenge. Emerging evidence from our work in humans and mice shows that endogenous amidated hormones synergize with GLP-1RAs to reduce glycated hemoglobin, and their absence promotes GLP-1RA resistance. This proposal explores the intricate mechanisms by which endogenous amidated hormones affect endogenous GLP-1 secretion, modulate its function, and influence the effectiveness of GLP-1RAs. Furthermore, it will investigate which…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.